Pneumococcal polysaccharide vaccine 23-valent - Beijing Minhai Biotechnology

Drug Profile

Pneumococcal polysaccharide vaccine 23-valent - Beijing Minhai Biotechnology

Alternative Names: 23-valent pneumococcal polysaccharide vaccine - Beijing Minhai Biotechnology

Latest Information Update: 26 Aug 2015

Price : $50

At a glance

  • Originator Beijing Minhai Biotechnology
  • Developer Beijing Minhai Biotechnology; Jiangsu Provincial Center for Disease Control and Prevention
  • Class Pneumococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Pneumococcal infections

Most Recent Events

  • 26 Aug 2015 Registered for Pneumococcal infections (In adolescents, In children, In the elderly, Prevention, In adults) in China (IM) before August 2015
  • 25 Aug 2015 Preregistration for Pneumococcal infections (In adolescents, In children, In the elderly, Prevention, In adults) in China (IM) before August 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top